ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Genomma Lab InternacionalB de CV's annualizedNet Income for the quarter that ended in Mar. 2026 was MXN1,979 Mil.
Genomma Lab InternacionalB de CV's average Total Assets over the quarter that ended in Mar. 2026 was MXN24,246 Mil. Therefore, Genomma Lab InternacionalB de CV's annualized ROA % for the quarter that ended in Mar. 2026 was 8.16%.
MEX:LABB'
s ROA % Range Over the Past 10 Years
Min: -10.08 Med: 6.56 Max: 8.1
Current: 6.66
During the past 13 years, Genomma Lab InternacionalB de CV's highest ROA % was 8.10%. The lowest was -10.08%. And the median was 6.56%.
MEX:LABB's ROA % is ranked better than 70.28% of 1006
companies
in the Drug Manufacturers industry
Industry Median: 2.685
vs MEX:LABB: 6.66
Genomma Lab InternacionalB de CV (MEX:LABB) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Genomma Lab InternacionalB de CV ROA % Related Terms
Genomma Lab InternacionalB de CV ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genomma Lab InternacionalB de CV ROA % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's ROA % distribution charts can be found below:
* The bar in red indicates where Genomma Lab InternacionalB de CV's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Genomma Lab InternacionalB de CV (MEX:LABB) has a ROA % of 8.16% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Genomma Lab InternacionalB de CV and its competitors. This is 24% above median its historical median of 6.56. According to the industry distribution chart, Genomma Lab InternacionalB de CV ranks #299 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 29.7%.
Is Genomma Lab InternacionalB de CV's ROA % too high?
Genomma Lab InternacionalB de CV's current ROA % of 8.16% is 24% above median its 10-year median of 6.56. The Drug Manufacturers industry median ROA % is 2.69. Genomma Lab InternacionalB de CV's value of 8.16% is 203.9% above this industry median. Based on the distribution chart, Genomma Lab InternacionalB de CV ranks #299 out of 1006 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Genomma Lab InternacionalB de CV has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genomma Lab InternacionalB de CV's ROA % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Genomma Lab InternacionalB de CV ranks #299 out of 1006 companies for ROA %. This puts Genomma Lab InternacionalB de CV in the upper half of its industry. The industry median ROA % is 2.69. Genomma Lab InternacionalB de CV's value of 8.16% is 203.9% above this benchmark. While the company's 10-year median is 6.56 vs. the industry median of 2.69, Genomma Lab InternacionalB de CV has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genomma Lab InternacionalB de CV's current ROA % of 8.16% is 203.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Genomma Lab InternacionalB de CV and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genomma Lab InternacionalB de CV's current ROA % is 8.16%, which is 24% above median its own 10-year median of 6.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genomma Lab InternacionalB de CV stock overvalued right now?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV (MEX:LABB) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN17.64, compared to a current price of MXN15.04 — trading 14.7% below its estimated fair value. The current ROA % is 8.16%, which is 24% above median its 10-year median of 6.56 and 203.9% above the Drug Manufacturers industry median of 2.69. Genomma Lab InternacionalB de CV's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Genomma Lab InternacionalB de CV (MEX:LABB), the current ROA % is 8.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genomma Lab InternacionalB de CV (MEX:LABB) Overvalued in 2026?
Based on GuruFocus' analysis, Genomma Lab InternacionalB de CV stock appears to be undervalued.
The current stock price of MXN15.04 is trading 14.7% below its estimated GF Value™ of MXN17.64.
GuruFocus considers Genomma Lab InternacionalB de CV to be Modestly Undervalued.
Key valuation signals for MEX:LABB:
ROA %: 8.16% (24% above median its 10-year median of 6.56)
GF Value™: MXN17.64 vs. price of MXN15.04 (14.7% below fair value)
Industry Position: 203.9% above the Drug Manufacturers median (#299 of 1006)
No single metric tells the full story. See the MEX:LABB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genomma Lab InternacionalB de CV Business Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
66GF Score
Get the complete analysis for MEX:LABB
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:LABB has been successfully added to your 
